Clinical Trial Update: Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC [NA]

View source ↗

Summary

A clinical trial update describes a not-yet-recruiting study of albumin-bound paclitaxel and dalpiciclib with AI in HR+/HER2- advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: Fujian Medical University | Conditions: HR+/HER2- Advanced Breast Cancer | NA | Status: NOT_YET_RECRUITING